Objective: To detail an easy approach to identify the changes that moxifloxacin and flunixin meglumine have caused in the dam of   female rats.
Design: Randomized controlled experimental study.
Animals: This study was conducted on thirty-five female (170-200 gm) mature white rats (170-200 gm) and clinically intact, 20 mature male albino rats for the purpose of mating.
Procedures:Once mating has occurred, this is considered the first day of pregnancy. Rats were randomly divided into seven groups 1) a control group 2) The moxifloxacin group 6 days 3) the moxifloxacin group 13 days 4) the flunixin meglumine group 6 days 5) the flunixin meglumine group 13 days 6) the moxifloxacin and flunixin meglumine mg group 6 days 7) the moxifloxacin and flunixin meglumine mg group on day 13. Rats were killed on the days specified for the sixth day and the thirteenth day. Blood and liver samples were collected for biochemical analysis of blood and tissue for pathological examination.
Results: Moxifloxacin and flunixin meglumine and their combination have been shown to have some negative effects in mothers of rats, so we recommend that caution be exercised when using moxifloxacin and flunixin meglumine during pregnancy. It was found that the tested drugs had caused a significant decrease in superoxide dismutase and glutathione levels compared to the control group. The histopathological examination of mothers, who were given moxifloxacin and flunixin meglumine and their mixtures, showed variable alterations in kidney, liver and placenta.
Conclusion and clinical relevance: From the above it is clear that moxifloxacin and flunixin meglumine and their combination have caused some negative effects for pregnant rats, so we recommend that you use caution when using moxifloxacin and flunixin meglumine during pregnancy.